V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214200 | 20080530 | null | null | Disease modification (D) | 2019-02-07 | 2019-03-08 | LANREOTIDE | 02 | N | LANREOTIDE | 100377814 |
| 20214201 | 20080531 | 1.64 | 59.95 | null | 2019-07-25 | 2019-08-13 | HCX | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100207983 |
| 20214203 | 20080532 | 1.8 | 65.6 | Palliative (P) | 2019-01-11 | 2019-01-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100899082 |
| 20214204 | 20080533 | 1.7 | null | Palliative (P) | 2018-09-24 | 2018-10-03 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100771201 |
| 20214205 | 20080534 | 1.73 | 90 | null | null | 2016-12-17 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101794001 |
| 20214206 | 20080535 | 1.61 | 1 | null | 2017-09-09 | 2017-09-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101809770 |
| 20214207 | 20080536 | 1.76 | 71.5 | Palliative (P) | 2016-08-20 | 2016-08-22 | HCX | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100279314 |
| 20214209 | 20080538 | 1.8 | 110 | Palliative (P) | 2019-09-03 | 2019-09-17 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100170850 |
| 20214210 | 20080539 | 1.7 | 61.6 | Palliative (P) | 2019-03-13 | 2019-03-13 | Trial Unspecified | Y | N | TRIAL | 100388765 |
| 20214211 | 20080540 | 0 | 108.5 | null | 2020-02-10 | 2020-02-27 | HCX (Cape + Cisp + Tras) - Load | null | N | LANREOTIDE | 100292186 |
| 20214213 | 20080541 | 1.71 | null | Palliative (P) | 2016-07-02 | 2016-07-02 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101392623 |
| 20214216 | 20080542 | null | 55.5 | Palliative (P) | 2018-01-24 | 2018-02-08 | Cape+Cisplatin+Trastuzumab Main | 02 | N | LANREOTIDE | 101466859 |
| 20214220 | 20080545 | 1.76 | 65 | Curative (C) | 2019-04-18 | 2019-05-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101508150 |
| 20214221 | 20080546 | 0 | 80.7 | null | 2017-06-07 | 2017-06-08 | LANREOTIDE | 02 | N | LANREOTIDE | 100764543 |
| 20214222 | 20080547 | 1.67 | null | Curative (C) | 2019-09-07 | 2019-10-06 | Cape+Cisplatin+Trastuzumab Load | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101655575 |
| 20214223 | 20080548 | 1.65 | 67 | Palliative (P) | 2017-11-30 | 2017-12-25 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100230760 |
| 20214224 | 20080549 | 1.57 | 82.9 | Neo-adjuvant (N) | 2017-09-02 | 2017-09-09 | Imatinib 400mg | 02 | N | IMATINIB | 100277831 |
| 20214226 | 20080550 | 1.56 | 92.4 | null | 2018-01-01 | 2018-01-03 | Trial Unspecified | Y | Y | TRIAL | 100279326 |
| 20214227 | 20080551 | 1.72 | 67 | Neo-adjuvant (N) | 2019-07-03 | 2019-07-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101716428 |
| 20214228 | 20080552 | 1.7 | 68.3 | Palliative (P) | 2018-12-05 | 2018-12-21 | Trial Unspecified | 01 | Y | TRIAL | 100049192 |
| 20214230 | 20080553 | 1.7 | 88.4 | Curative (C) | 2017-10-03 | 2017-10-03 | Fluorouracil+Mitomycin+RT (Bladder) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101576125 |
| 20214231 | 20080554 | 1.49 | 52 | null | 2018-06-03 | 2018-06-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100868147 |
| 20214232 | 20080555 | 1.7 | 76.3 | Curative (C) | 2016-09-13 | 2016-09-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101058652 |
| 20214233 | 20080556 | 1.63 | 103.25 | Palliative (P) | 2018-11-13 | 2018-12-13 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100402158 |
| 20214234 | 20080557 | 1.72 | 77 | Curative (C) | 2017-12-24 | 2018-01-10 | FLUOROURACIL + MITOMYCIN + RT | N | null | FLUOROURACIL + MITOMYCIN + RT | 101216849 |
| 20214235 | 20080558 | 1.47 | 96.8 | null | 2017-12-22 | 2018-02-08 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100125448 |
| 20214236 | 20080559 | 1.58 | 0 | Palliative (P) | 2020-07-09 | 2020-08-06 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101494917 |
| 20214237 | 20080560 | 1.74 | 61 | 03 | 2016-07-29 | 2016-08-17 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100453083 |
| 20214238 | 20080561 | 1.79 | 60.5 | Palliative (P) | 2018-03-01 | 2018-03-16 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101073555 |
| 20214239 | 20080562 | 1.75 | 0 | Curative (C) | 2016-04-16 | 2016-05-01 | FLUOROURACIL + MITOMYCIN + RT | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101404840 |
| 20214240 | 20080563 | 1.76 | 52.8 | Palliative (P) | 2018-05-06 | 2018-05-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100319630 |
| 20214241 | 20080564 | 1.69 | 57 | Palliative (P) | 2016-06-21 | 2016-06-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | TRIAL | 101363183 |
| 20214242 | 20080565 | 1.68 | null | Palliative (P) | 2018-05-06 | 2018-05-10 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101248653 |
| 20214243 | 20080566 | 1.72 | 85.6 | Palliative (P) | 2018-02-10 | 2018-03-08 | Trial Unspecified | 01 | N | TRIAL | 100580680 |
| 20214244 | 20080567 | 1.51 | 86.3 | Palliative (P) | 2016-11-14 | 2016-11-30 | HCX | 02 | N | IMATINIB | 101565299 |
| 20214245 | 20080568 | null | null | Palliative (P) | 2016-12-10 | 2016-12-10 | IMATINIB | 2 | N | IMATINIB | 101034897 |
| 20214247 | 20080569 | 1.66 | null | Palliative (P) | 2018-01-26 | 2018-02-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101806069 |
| 20214248 | 20080570 | 1.66 | 0 | Palliative (P) | 2017-09-07 | 2017-09-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101481648 |
| 20214249 | 20080571 | 1.73 | null | Curative (C) | 2019-01-18 | 2019-01-28 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101006441 |
| 20214250 | 20080572 | 1.52 | 66.8 | Palliative (P) | 2018-06-15 | 2018-07-05 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101345757 |
| 20214251 | 20080573 | 1.84 | 81.75 | Palliative (P) | 2018-09-30 | 2018-10-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101496212 |
| 20214252 | 20080574 | 1.57 | 113.8 | null | 2016-10-22 | 2016-10-22 | LANREOTIDE | 02 | N | LANREOTIDE | 101170049 |
| 20214253 | 20080575 | 1.62 | 67.7 | Palliative (P) | 2017-10-10 | 2017-10-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101184334 |
| 20214254 | 20080576 | 1.56 | 85 | Palliative (P) | 2019-11-12 | 2019-11-20 | Trial Unspecified | 1 | N | TRIAL | 100566402 |
| 20214257 | 20080578 | 1.76 | 72.2 | Palliative (P) | 2019-06-19 | 2019-07-19 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100400433 |
| 20214258 | 20080579 | null | 66.9 | Disease modification (D) | 2021-08-20 | 2021-08-20 | LANREOTIDE | N | N | LANREOTIDE | 100977924 |
| 20214260 | 20080581 | 1.7 | 68.2 | Curative (C) | 2019-10-28 | 2019-11-13 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100524747 |
| 20214261 | 20080582 | 1.61 | 97 | Curative (C) | 2016-05-27 | 2016-06-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100647275 |
| 20214262 | 20080583 | 1.79 | 73.6 | Palliative (P) | 2019-11-18 | 2019-12-05 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100604332 |
| 20214264 | 20080584 | 1.65 | 120 | Not known (9) | 2018-09-06 | 2018-09-30 | Fluorouracil+Mitomycin+RT (Bladder) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100963251 |